JPH0840824A - Cosmetic - Google Patents

Cosmetic

Info

Publication number
JPH0840824A
JPH0840824A JP7179581A JP17958195A JPH0840824A JP H0840824 A JPH0840824 A JP H0840824A JP 7179581 A JP7179581 A JP 7179581A JP 17958195 A JP17958195 A JP 17958195A JP H0840824 A JPH0840824 A JP H0840824A
Authority
JP
Japan
Prior art keywords
lactoferrin
cosmetic
secretory immunoglobulin
secretory
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7179581A
Other languages
Japanese (ja)
Inventor
Tomio Okada
富雄 岡田
Hiroshi Tanaka
浩 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nonogawa Shoji Ltd
Original Assignee
Nonogawa Shoji Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nonogawa Shoji Ltd filed Critical Nonogawa Shoji Ltd
Priority to JP7179581A priority Critical patent/JPH0840824A/en
Publication of JPH0840824A publication Critical patent/JPH0840824A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PURPOSE:To obtain a cosmetic for improving skin roughness. CONSTITUTION:The characteristic of the cosmetic comprises containing secretory immunoglobulin A and lactoferrin. The secretory immunoglobulin A is contained in a mucosal secretory solution and plays an important role on biophylaxis in a local immune mechanism. The lactoferrin is a glucoprotein and takes iron ions from bacteria to exhibit an antibacterial effect. The preparation forms of the cosmetic include creams, lotions, emulsions, foundations, lip sticks, eye shadows, and hair liquids.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は分泌型イムノグロブリン
Aとラクトフェリンを含有した化粧料に関する。
TECHNICAL FIELD The present invention relates to a cosmetic containing secretory immunoglobulin A and lactoferrin.

【0002】[0002]

【従来の技術】毛嚢性膿皮症や汗腺性膿皮症などの感染
性皮膚炎は黄色ブドウ球菌や連鎖球菌といった化膿菌が
原因として引き起こされる。また、アトピー性皮膚炎の
原因の一つとして皮膚上で増殖する黄色ブドウ球菌が原
因することが分かっている。このため、従来から抗生物
質、殺菌剤や抗菌剤を添加した皮膚外用剤がそれらの治
療に使用されてきた。また、従来の化粧料には黄色ブド
ウ球菌のみの増殖を抑制するような物質を配合したもの
はなった。
2. Description of the Related Art Infectious dermatitis such as pyoderma pyoderma and pyoderma pyoderma is caused by Pseudomonas aeruginosa such as Staphylococcus aureus and Streptococcus. Further, it is known that one of the causes of atopic dermatitis is Staphylococcus aureus that grows on the skin. Therefore, external preparations for skin to which antibiotics, bactericides and antibacterial agents have been added have been conventionally used for their treatment. In addition, there has been no conventional cosmetic containing a substance that suppresses the growth of only Staphylococcus aureus.

【0003】[0003]

【発明が解決しようとする課題】しかし、殺菌剤や防腐
剤のなかには皮膚刺激性などの点で,人体に対する安全
性に問題のあるものがあり、また、これらの薬剤を含む
外用剤は、化膿菌や一般細菌に限らず表皮ブドウ球菌な
どの皮膚常在菌に対しても殺菌効果を示すため、連日の
使用により皮膚常在菌の微妙なバランスをくずしてしま
うといった、いわゆるエコロジーの観点から時には好ま
しくない事態を引き起こすことが指摘されている。例え
ば、表皮ブドウ球菌はそれが有するリパーゼの作用によ
って皮脂中のトリグリセライドを分解し皮膚上のpHを
酸性に保つ皮膚浄化作用を有している。そこで、かかる
抗生物質、殺菌剤や抗菌剤を使用せずに表皮ブドウ球菌
には影響を与えることなく黄色ブドウ球菌や連鎖球菌等
の化膿菌を選択的に抑制することができ、かつ生体に影
響を与えず安全性の高い物質の探求が行われてきた。
However, some of the bactericides and antiseptics have a problem in safety for human body due to skin irritation, and the external preparations containing these agents are suppuratives. Not only fungi and general bacteria but also a bactericidal effect against skin resident bacteria such as Staphylococcus epidermidis, it may sometimes break the delicate balance of skin resident bacteria by daily use, sometimes from the viewpoint of so-called ecology It has been pointed out that it causes an unfavorable situation. For example, Staphylococcus epidermidis has a skin-purifying action of degrading triglyceride in sebum by the action of its lipase and keeping the pH on the skin acidic. Therefore, it is possible to selectively suppress Pseudomonas aeruginosa such as Staphylococcus aureus and Streptococcus without affecting the Staphylococcus epidermidis without using such antibiotics, bactericides or antibacterial agents, and affect the living body. There has been a search for highly safe substances without giving.

【0004】分泌型イムノグロブリンAとラクトフェリ
ンは消化管や気道上部の粘膜分泌液に含まれ、病原微生
物に対し制菌、殺菌効果を有することが従来知られてい
た。我々は皮膚の汗中にもこの分泌型イムノグロブリン
Aとラクトフェリンが分泌されていることを明かとし、
さらにこれらが表皮常在菌の中で黄色ブドウ球菌に選択
的に菌の増殖抑制効果を有することを発見した。このた
めに健康人の皮膚常在菌には黄色ブドウ球菌は殆ど観察
されないのであろうと推測される。
It has been conventionally known that secretory immunoglobulin A and lactoferrin are contained in mucosal secretions in the digestive tract and upper respiratory tract and have bactericidal and bactericidal effects against pathogenic microorganisms. We revealed that secretory immunoglobulin A and lactoferrin are also secreted in the sweat of the skin,
Furthermore, it was discovered that these have a selective growth inhibitory effect on Staphylococcus aureus among the indigenous epidermis. Therefore, it is presumed that Staphylococcus aureus is hardly observed in the skin-resident bacteria of healthy people.

【0005】また、健康人においても乾燥時、特に冬季
には黄色ブドウ球菌が増殖し易く肌荒れを起こし易くな
る。これは、発汗量の少ないために皮膚上に充分の分泌
型イムノグロブリンAとラクトフェリンの分泌量が少な
いためと考えられる。そこで、この分泌型イムノグロブ
リンAとラクトフェリンを外用することによって肌荒れ
を改善することを認め本発明を完成するに至った。
Further, even in a healthy person, Staphylococcus aureus easily grows when dry, especially in winter, and the skin is apt to become rough. It is considered that this is because the amount of secreted immunoglobulin A and lactoferrin secreted on the skin is small due to the small amount of sweating. Therefore, it was confirmed that external use of this secretory immunoglobulin A and lactoferrin improves rough skin and the present invention has been completed.

【0006】[0006]

【課題を解決するための手段】すなわち、本発明は分泌
型イムノグロブリンAとラクトフェリンを配合した化粧
料である。本発明に用いる分泌型イムノグロブリンAは
2分子のイムノグロブリンAにSecretory Compo-nentと
J chainが結合した分子量約385,000のイムノグロ
ブリンで粘膜分泌液に含まれ、局所免疫機構として生体
防御機構に重要な役割を果している。また、ラクトフェ
リンは分子量約88、000の糖タンパクで、細菌から
鉄イオンを奪うことにより殺菌効果を示す。分泌型イム
ノグロブリンAとラクトフェリンは共に母乳にもっとも
多く含まれている。なお、その由来に関しては人或は動
物の如何を問わない。本外用剤にはこの母乳より分離精
製(BennetR, et al.: A solid-phaseradioimunoassay f
or the measurement of lactoferrin in human plasma:
Variations with age, sex, and disease. J Lab Clin
Med88:156,1976)したものを、あるいは市販品を用いる
ことも出来る。
That is, the present invention is a cosmetic composition containing secretory immunoglobulin A and lactoferrin. The secretory immunoglobulin A used in the present invention is composed of two molecules of immunoglobulin A and a secretory compo-nent.
It is an immunoglobulin with a molecular weight of about 385,000 bound to J chain, which is contained in mucosal secretions and plays an important role in the biological defense mechanism as a local immune mechanism. Lactoferrin is a glycoprotein having a molecular weight of about 88,000 and exhibits a bactericidal effect by depriving bacteria of iron ions. Both secretory immunoglobulin A and lactoferrin are most abundant in human milk. In addition, it does not matter whether it is a human or an animal. This external preparation was separated and purified from this milk (Bennet R, et al .: A solid-phase radioimunoassay f
or the measurement of lactoferrin in human plasma:
Variations with age, sex, and disease. J Lab Clin
Med88: 156,1976) or a commercially available product can be used.

【0007】本発明の化粧料に用いる分泌型イムノグロ
ブリンAとラクトフェリンの配合量は それぞれ、個々
の化粧料全組成の0.0001〜 10重量パーセント、好まし
くは0.001〜5重量パーセントの割合になるように添加さ
れる。0.0001重量パーセント未満では黄色ブドウ球菌抑
制効果に乏しく、10重量パーセントを越えて配合すると
製品の安定性を保つことが難しくなる。
The amount of secretory immunoglobulin A and lactoferrin used in the cosmetic of the present invention is 0.0001 to 10% by weight, preferably 0.001 to 5% by weight, based on the total composition of each cosmetic. To be done. If it is less than 0.0001% by weight, the Staphylococcus aureus inhibitory effect is poor, and if it exceeds 10% by weight, it becomes difficult to maintain the stability of the product.

【0008】本発明の化粧料とは、形態的にはクリー
ム、ローション、乳液、ファンデーション、口紅、アイ
シャドー、液体整髪料等が含まれる。
The cosmetics of the present invention include morphologically creams, lotions, emulsions, foundations, lipsticks, eye shadows, liquid hair styling products and the like.

【0009】本発明の化粧料には通常の成分、例えば、
油性成分(例えば、スクワラン、ワセリン、オリーブ
油、ホホバ油)、界面活性剤(例えば、セスキオレイン
酸ソルビタン、モノステアリン酸グリセリン、ラウリル
硫酸ナトリウム)、保湿剤(プロピレングリコール、グ
リセリン)、アルコール(セチルアルコール)、増粘
剤、防腐剤、紫外線吸収剤、色剤、香料等を添加するこ
とができる。
[0009] The cosmetics of the present invention have the usual ingredients such as
Oily ingredients (eg squalane, petrolatum, olive oil, jojoba oil), surfactants (eg sorbitan sesquioleate, glyceryl monostearate, sodium lauryl sulfate), moisturizers (propylene glycol, glycerin), alcohols (cetyl alcohol) , Thickeners, preservatives, ultraviolet absorbers, colorants, fragrances and the like can be added.

【0010】[0010]

【実施例】次に実施例をあげて更に詳しく説明するが、
本発明はこれによって限定されるものではない。配合量
は重量%である。
[Examples] Next, more detailed description will be given with reference to Examples.
The present invention is not limited to this. The blending amount is% by weight.

【0011】実施例ー1 クリーム (1)スクワラン 11.5 (2)セチルアルコール 2.5 (3)ポリオキシエチレン(20) 1.0 ソルビタンモノステアレート (4)ポリオキシエチレン(20) 2.5 セチルエーテル (5)1、3ブチレングリコール 4.0 (6)プロピレングリコール 3.5 (7)パラオキシ安息香酸メチル 0.03 (8)分泌型イムノグロブリンA 3.0 (9)ラクトフェリン 3.0 (10)精製水を加えて100とする。 成分(1)〜(4)を加熱溶解して混合し、70℃に保
ち油相とする。成分(5)〜(7)を(10)に均一に
分散し、75℃に保ち水相とする。油相に水相を加えて
乳化分散し、40℃まで冷却した後、成分(8)、
(9)を加えて溶解させ、再び30℃まで冷却して製品
とする。
Example 1 Cream (1) Squalane 11.5 (2) Cetyl alcohol 2.5 (3) Polyoxyethylene (20) 1.0 Sorbitan monostearate (4) Polyoxyethylene (20) 2. 5 Cetyl ether (5) 1,3 Butylene glycol 4.0 (6) Propylene glycol 3.5 (7) Methyl paraoxybenzoate 0.03 (8) Secretory immunoglobulin A 3.0 (9) Lactoferrin 3.0 (10) Add purified water to make 100. Components (1) to (4) are dissolved by heating and mixed, and the mixture is kept at 70 ° C. to form an oil phase. Components (5) to (7) are uniformly dispersed in (10) and kept at 75 ° C to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify and disperse, and after cooling to 40 ° C., the component (8),
(9) is added and dissolved, and the product is cooled again to 30 ° C.

【0012】実施例ー2 クリーム (1)スクワラン 5.0 (2)オリーブ油 5.5 (3)ステアリン酸 3.0 (4)ミツロウ 2.0 (5)ミリスチン酸オクチルドデシル 3.5 (6)ポリオキシエチレン(20) 2.5 セチルエーテル (7)ベヘニルアルコール 1.5 (8)グリセリンモノステアレート 2.5 (9)1、3ブチレングリコール 8.5 (10)ラクトフェリン 0.1 (11)分泌型イムノグロブリンA 0.1 (12)精製水を加えて100とする。 成分(1)〜(8)を加熱溶解して混合し、70℃に保
ち油相とする。成分(9)、(12)を75℃に保ち水
相とする。油相に水相を加えて乳化分散し、40℃まで
冷却した後、成分(10)、(11)を加えて溶解さ
せ、再び30℃まで冷却して製品とする。
Example 2 Cream (1) Squalane 5.0 (2) Olive Oil 5.5 (3) Stearic Acid 3.0 (4) Beeswax 2.0 (5) Octyldodecyl Myristate 3.5 (6) Polyoxyethylene (20) 2.5 Cetyl ether (7) Behenyl alcohol 1.5 (8) Glycerin monostearate 2.5 (9) 1, 3 Butylene glycol 8.5 (10) Lactoferrin 0.1 (11) Secretion Immunoglobulin A 0.1 (12) Purified water is added to 100. The components (1) to (8) are dissolved by heating and mixed, and the mixture is kept at 70 ° C. to obtain an oil phase. The components (9) and (12) are kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify and disperse, and the mixture is cooled to 40 ° C., then the components (10) and (11) are added and dissolved, and the mixture is cooled to 30 ° C. again to obtain a product.

【0013】実施例ー3 口紅 (1)ヒマシ油 45.0 (2)オリーブアルコール 25.0 (3)ミツロウ 5.0 (4)パラフィンワックス130F 10.2 (5)キャンデリラロウ 4.2 (6)カルナウバロウ 2.2 (7)二酸化チタン 2.0 (8)赤色202号 0.5 (9)赤色204号 2.5 (10)赤色227号A1レーキ 2.5 (11)橙色201号 0.2 (12)分泌型イムノグロブリンA 0.2 (13)ラクトフェリン 0.3 (14)香料 0.2 成分(7)〜(11)を成分(1)の一部に分散し、顔
料ベースとする。次に成分(2)〜(6)及び成分
(1)の残りを80〜85℃で溶解し、前記顔料ベース
及び成分(12)〜(14)を加えてかき混ぜ、脱気し
て所定の容器に流し込み冷却固化して製品とする。
Example 3 Lipstick (1) Castor oil 45.0 (2) Olive alcohol 25.0 (3) Beeswax 5.0 (4) Paraffin wax 130F 10.2 (5) Candelilla wax 4.2 ( 6) Carnauba wax 2.2 (7) Titanium dioxide 2.0 (8) Red No. 202 0.5 (9) Red No. 204 2.5 (10) Red No. 227 A1 Lake 2.5 (11) Orange No. 201 0 .2 (12) Secretory immunoglobulin A 0.2 (13) Lactoferrin 0.3 (14) Perfume 0.2 Components (7) to (11) are dispersed in a part of the component (1) to form a pigment base. To do. Next, the components (2) to (6) and the rest of the component (1) are melted at 80 to 85 ° C., the pigment base and the components (12) to (14) are added, and the mixture is stirred, deaerated and put into a predetermined container. It is poured into and cooled and solidified to obtain a product.

【0014】実施例ー4 乳液状ファンデーション (1)ステアリン酸 2.4 (2)モノステアリン酸 プロピレングリコール 2.0 (3)セトステアリルアルコール 0.2 (4)液状ラノリン 2.0 (5)流動パラフィン 3.0 (6)ミリスチン酸イソプロピル 8.5 (7)パラオキシ安息香酸ブチル 0.01 (8)精製水 58.6 (9)カルボキシメチルセルロース ナトリウム 0.2 (10)ベントナイト 0.5 (11)プロピレングリコール 4.0 (12)トリエタノールアミン 1.1 (13)パラオキシ安息香酸メチル 0.02 (14)酸化チタン 8.0 (15)タルク 4.0 (16)着色顔料 5.0 (17)分泌型イムノグロブリンA 0.05 (18)ラクトフェリン 0.05 (19)香料 0.1 成分(10)を成分(8)によく膨潤させる。これに成
分(11)を分散させた成分(9)を加えて溶解し、続
いて成分(12)、(13)を溶解し水相とする。成分
(1)〜(7)を加熱溶解し、80℃に保ち油相とす
る。水相に、良く混合し粉砕機に通し粉砕した成分(1
6)を加え、ホモミキサーで撹拌し75℃に保つ。この
水相に油相をかき混ぜながら加え、冷却し、45℃で成
分(17)〜(19)を加え、撹拌冷却後に製品とす
る。
Example 4 Milky liquid foundation (1) Stearic acid 2.4 (2) Monostearate propylene glycol 2.0 (3) Cetostearyl alcohol 0.2 (4) Liquid lanolin 2.0 (5) Fluid Paraffin 3.0 (6) Isopropyl myristate 8.5 (7) Butyl paraoxybenzoate 0.01 (8) Purified water 58.6 (9) Sodium carboxymethyl cellulose 0.2 (10) Bentonite 0.5 (11) Propylene glycol 4.0 (12) Triethanolamine 1.1 (13) Methyl paraoxybenzoate 0.02 (14) Titanium oxide 8.0 (15) Talc 4.0 (16) Color pigment 5.0 (17) Secretory immunoglobulin A 0.05 (18) Lactoferrin 0.05 (19) Perfume 0.1 component ( 0) is good swell component (8). The component (9) in which the component (11) is dispersed is added to and dissolved therein, and then the components (12) and (13) are dissolved to form an aqueous phase. Components (1) to (7) are melted by heating and kept at 80 ° C. to form an oil phase. Ingredients (1
Add 6), stir with homomixer and keep at 75 ° C. The oil phase is added to this aqueous phase while stirring and cooled, and the components (17) to (19) are added at 45 ° C., and the product is obtained after stirring and cooling.

【0015】[0015]

【発明の効果】本発明による分泌型イムノグロブリンA
とラクトフェリンを配合した化粧料の荒れ肌に対する改
善効果を試験例によって説明する。
The secretory immunoglobulin A according to the present invention
The improvement effect of the cosmetics containing lactoferrin and lactoferrin on rough skin will be described with reference to test examples.

【0016】実験例 1 皮膚常在菌の黄色ブドウ球菌,表皮ブドウ球菌とミクロ
コッカス属の Micrococcus luteurs 12708 の3種に付
いて人由来の分泌型イムノグロブリンAとラクトフェリ
ン(シグマ社製)の菌増殖抑制効果を検討した。方法は
mlあたり10,000個の菌を接種したトリプトソイブイヨン
培地(栄研化学)中に分泌型イムノグロブリンAとラク
トフェリンの単品をまた分泌型イムノグロブリンAとラ
クトフェリンを等量に混合したものをそれぞれ1mlあた
り1mg添加し、それらの3種の皮膚常在菌の増殖抑制効
果を菌接種後3時間と6時間後に観察した。その結果、
表1に示すごとく分泌型イムノグロブリンAとラクトフ
ェリンを共に混合したものが試験した3種の菌のうち黄
色ブドウ球菌にのみ菌の増加が見られず、したがって、
分泌型イムノグロブリンAとラクトフェリンの混合物が
黄色ブドウ球菌にのみ選択的に増殖抑制効果を有するこ
とが明かとなった。
Experimental Example 1 Proliferation of human-derived secretory immunoglobulin A and lactoferrin (manufactured by Sigma) for three species of Staphylococcus aureus, Staphylococcus epidermidis, and Micrococcus luteurs 12708 of the genus Micrococcus The suppression effect was examined. The way is
1 mg of secretory immunoglobulin A and lactoferrin mixed in equal amounts of secretory immunoglobulin A and lactoferrin in tryptosoy broth medium (Eiken Chemical Co., Ltd.) inoculated with 10,000 bacteria per ml. The effect of inhibiting the growth of these three types of skin-resident bacteria was added and observed 3 and 6 hours after inoculation. as a result,
As shown in Table 1, the mixture of secretory immunoglobulin A and lactoferrin showed no increase in Staphylococcus aureus among the three kinds of bacteria tested, and therefore,
It was revealed that a mixture of secretory immunoglobulin A and lactoferrin has a selective growth inhibitory effect only on S. aureus.

【0017】[0017]

【表1】 増殖量:接種時の菌数に対する増殖倍数 sIgA=分泌型IgA、 LTF=ラクトフェリン A:黄色ブドウ球菌 B:表皮ブドウ球菌 C: ミクロコッカス属[Table 1] Proliferation amount: multiple of the number of bacteria at the time of inoculation sIgA = secretory IgA, LTF = lactoferrin A: Staphylococcus aureus B: Staphylococcus epidermidis C: Micrococcus

【0018】実験例 2 荒れ肌症の女性20名を対照に、実施例ー1のクリーム
を連日10日間使用させ、荒れ肌改善試験を行った。試
験はハーフブラインド法で顔面の片側に実施例ー1のク
リームを、また、一方に比較対照として実施例ー1より
分泌型イムノグロブリンAとラクトフェリンを除いたも
のを使用させた。判定は、比較対照に比べて、どの程度
改善されたかによって行った。
Experimental Example 2 A rough skin improvement test was carried out by using the cream of Example 1 for 10 days every day against 20 women with rough skin as a control. In the test, the cream of Example 1 was used on one side of the face by the half blind method, and the one from which secretory immunoglobulin A and lactoferrin were removed from Example 1 was used as a comparative control on one side. The judgment was made based on the degree of improvement compared with the control.

【0019】(判定基準) 1、著しく改善された。 2、改善された。 3、やや改善された。 4、改善がみられなかった。(Criteria for Judgment) 1. Remarkably improved. 2, improved. 3, slightly improved. 4. No improvement was observed.

【0020】[0020]

【表2】表2 結果 ─────────────────── 判 定 人数 ─────────────────── 1 4 (20%) 2 11 (55 ) 3 3 (15 ) 4 2 (10 ) ───────────────────[Table 2] Table 2 Results ─────────────────── Judgment number of people ──────────────────── 14 (20%) 2 11 (55) 3 3 (15) 4 2 (10) ───────────────────

【0021】表2に示すごとく、分泌型イムノグロブリ
ンAとラクトフェリン配合クリームのほうが肌荒れ改善
効果が75%認められ、本発明の化粧料が肌荒れに対し
有効であることが判った。
As shown in Table 2, the cream containing secretory immunoglobulin A and lactoferrin was found to have a skin roughening improving effect of 75%, and it was found that the cosmetic composition of the present invention is effective for rough skin.

【0022】[安全性]分泌型イムノグロブリンAとラ
クトフェリンのそれぞれの20%水溶液に付いてウサギ
を用いた一次刺激性試験、モルモットを用いた感作試
験、ラビットの眼を用いた眼瞼刺激性試験を実施した結
果、共に陽性反応は認められず、安全であることが確認
された。
[Safety] Primary irritation test in rabbits with 20% aqueous solutions of secretory immunoglobulin A and lactoferrin, sensitization test in guinea pigs, eyelid irritation test in rabbit eyes As a result, it was confirmed that no positive reaction was observed, and that it was safe.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】分泌型イムノグロブリンAとラクトフェリ
ンを含有することを特徴とする化粧料。
1. A cosmetic comprising a secretory immunoglobulin A and lactoferrin.
JP7179581A 1995-06-21 1995-06-21 Cosmetic Pending JPH0840824A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7179581A JPH0840824A (en) 1995-06-21 1995-06-21 Cosmetic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7179581A JPH0840824A (en) 1995-06-21 1995-06-21 Cosmetic

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP62292738A Division JPH0813754B2 (en) 1987-11-19 1987-11-19 Topical skin

Publications (1)

Publication Number Publication Date
JPH0840824A true JPH0840824A (en) 1996-02-13

Family

ID=16068236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7179581A Pending JPH0840824A (en) 1995-06-21 1995-06-21 Cosmetic

Country Status (1)

Country Link
JP (1) JPH0840824A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001172176A (en) * 1999-10-06 2001-06-26 Sunstar Inc Skin improver
JP2004352669A (en) * 2003-05-29 2004-12-16 Snow Brand Milk Prod Co Ltd Lactoferrin composition
JP2010180219A (en) * 2010-03-04 2010-08-19 Snow Brand Milk Prod Co Ltd Lactoferrin composition
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
JP2001172176A (en) * 1999-10-06 2001-06-26 Sunstar Inc Skin improver
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
JP2004352669A (en) * 2003-05-29 2004-12-16 Snow Brand Milk Prod Co Ltd Lactoferrin composition
JP4592260B2 (en) * 2003-05-29 2010-12-01 雪印乳業株式会社 Lactoferrin composition
JP2010180219A (en) * 2010-03-04 2010-08-19 Snow Brand Milk Prod Co Ltd Lactoferrin composition

Similar Documents

Publication Publication Date Title
JP3513873B2 (en) External preparation for skin
US6040347A (en) Treatment of seborrhoea/cutaneous disorders with octoxyglycerol
JPH1053510A (en) Composition for external use
JPH08301752A (en) Active substances to bacteria,filamentous fungus and virus
JP2003081761A (en) Emulsified composition
JPH07330579A (en) Composition containing superoxide dismutase and porphyrin
JPS63192705A (en) External agent for skin
JPH10182346A (en) Cosmetic
JPH0840824A (en) Cosmetic
JPH09175991A (en) Cosmetic and composition for skin containing active amounts of uric acid and uricase
JP3513872B2 (en) External preparation for skin
US20020164360A9 (en) Use of polyamino acid derivatives to treat seborrhoea and the associated skin disorders
JP2000159632A (en) Skin antimicrobial composition
JP2694756B2 (en) Cosmetics containing divalent and trivalent iron salts
JP3658626B2 (en) Cosmetics and quasi drugs
JP5264829B2 (en) Antiseptic disinfectant and cosmetic composition
JP2004067626A (en) External preparation composition
JPH11302147A (en) Cosmetic
JPH01135726A (en) Skin external preparation
JP2020525423A (en) New use
JP2780805B2 (en) New skin external preparation composition
JPH06321734A (en) Make-up cosmetic
JP2003104831A (en) Skin care preparation
JPH11279023A (en) Composition for external use
JPH10182312A (en) Antiseptic system and composition for cosmetic or pharmaceutical containing the same